Comparison
Abaloparatid vs. Melanotan II
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
247062-33-5
121062-08-6
Molecular weight
3960.6 g/mol
1024.18 g/mol
Half-life
1.7 h
1 h
Sequence
Ala-Val-Ser-Glu-His-Gln-Leu-Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His-Thr-Ala-NH2Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2Mechanism of action
Abaloparatid
Abaloparatide is a synthetic analogue of the first 34 amino acids of parathyroid hormone-related protein (PTHrP). Like parathyroid hormone and teriparatide it binds the PTH-1 receptor, but the literature describes it as preferentially engaging the so-called RG conformation of the receptor, which is associated with shorter signaling duration. As for the entire drug class, intermittent receptor activation is regarded as the mechanistic basis for the stimulation of bone-forming osteoblasts observed in studies, whereas continuously elevated exposure would tend to favor bone resorption. From this binding behavior the literature derives a discussed balance between bone formation and bone resorption.
Melanotan II
Melanotan II binds non-selectively to all five melanocortin-receptor subtypes (MC1R-MC5R). Via MC1R in melanocytes, eumelanin synthesis is stimulated (pigmenting effect). Via MC4R and MC3R in the CNS, appetite, sexual function and blood pressure are modulated. The cyclic structure and D-amino acids increase stability compared to natural α-MSH.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
4
9
of which in humans
4
5
Effects recorded
4
4
Open conflicts
1
1
Documented adverse events
2
6
Legal status
Full entries
Frequently asked questions
- What is the difference between Abaloparatid and Melanotan II?
- Abaloparatid is classified as "Research other", while Melanotan II is classified as "Research other". Abaloparatid: Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile. Melanotan II: Cyclic hepta-peptide and non-selective melanocortin-receptor agonist. Originally researched at the University of Arizona as a sun-protection concept — never approved as a medicine. Widespread on the black market; regulatory warnings for cardiovascular and oncological risks. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Abaloparatid or Melanotan II?
- The highest available evidence level is "Human RCT" for Abaloparatid and "Human trial" for Melanotan II. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Abaloparatid and Melanotan II in Germany and the United States?
- Germany: Abaloparatid — Prescription, Melanotan II — Unapproved. United States: Abaloparatid — Prescription, Melanotan II — Unapproved. These are factual summaries with source and review date on the individual pages.